Early results already showed a significant improvement in DFS for patients with PD-L1-positive stage II to IIIA NSCLC (HR 0.66; 95% CI 0.50–0.88) that led to Food and Drug Administration (FDA) approval as an adjuvant treatment following resection and platinum-based chemotherapy for this population. Here, CD274 is linked to non-small cell lung carcinoma.